Ryali Sriram 4
4 · Eiger BioPharmaceuticals, Inc. · Filed Mar 11, 2022
Insider Transaction Report
Form 4
Ryali Sriram
Chief Financial Officer
Transactions
- Award
Common Stock
2022-03-11+24,000→ 43,832 total - Award
Stock Option (Right to Buy)
2022-03-11+143,000→ 143,000 totalExercise: $5.10Exp: 2032-03-10→ Common Stock (143,000 underlying)
Footnotes (3)
- [F1]Represents shares underlying Restricted Stock Units award that will vest as to 33.3% on each of the first, second and third anniversaries of the grant date of March 11, 2022.
- [F2]The option vests in 48 equal monthly installments commencing on the grant date of March 11, 2022, subject to the Reporting Person's continuous service as of such date.
- [F3]Includes shares purchased under the Issuer's Employee Stock Purchase Plans as follows: 434 shares on September 5, 2020, 585 shares on September 3, 2021, and 661 shares on March 5, 2022.